Norvēģija - norvēģu - Statens legemiddelverk

consilient health limited - kolekalsiferol - kapsel, myk - 25000 iu

Norvēģija - norvēģu - Statens legemiddelverk

consilient health limited - kolekalsiferol - kapsel, myk - 50000 iu

Norvēģija - norvēģu - Statens legemiddelverk

bristol-myers squibb ab - triamcinolonacetonid - injeksjonsvæske, suspensjon - 40 mg/ ml

Norvēģija - norvēģu - Statens legemiddelverk

takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottablett - 1200 mg

Norvēģija - norvēģu - Statens legemiddelverk

aspen pharma trading limited - mivakuriumklorid - injeksjonsvæske, oppløsning - 2 mg/ ml

Norvēģija - norvēģu - Statens legemiddelverk

aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 mg

Norvēģija - norvēģu - Statens legemiddelverk

aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 mg

Norvēģija - norvēģu - Statens legemiddelverk

aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 5 mg

Norvēģija - norvēģu - Statens legemiddelverk

consilient health limited - kalsiumkarbonat / kolekalsiferol - tyggetablett med appelsinsmak - 500 mg / 800 iu

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.